Testing RSC-1255 in advanced cancers with RAS changes
Part of Cancer, Digestive system, Hormones & metabolism, Lungs & breathing clinical trials.
This early study (Phase 1) tests a new drug, RSC-1255, in people with advanced or metastatic cancers that have RAS mutations. It’s mainly focused on whether the treatment can be given safely and at what dose, and to see if it may shrink tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older with advanced or metastatic cancer that has either stopped responding to standard treatment or you cannot tolerate it
- Your doctor can measure your tumors with scans and/or lab tests for this trial
- You are well enough to take part (performance status that the trial describes as ECOG)
- Your cancer testing shows RAS mutation in a tissue-agnostic tumor, or you have glioblastoma (with or without RAS mutation)
- You are not currently receiving cancer treatment at the time you enroll
- No major ongoing health problems or heart/ECG problems that could make the study unsafe
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called RMC-5127 for people with advanced solid tumors that have a specific KRAS G12V mutation. The study aims to see if this targeted therapy can help when other treatments have stopped working or caused side effects.
This trial tests a new drug called GFH276 combined with either cetuximab or chemotherapy for people with certain cancers that have a specific genetic change called a RAS mutation. It focuses on solid tumors and pancreatic cancer (PDAC) and aims to see if the combination is safe and effective.
This trial is testing a new drug called BG-85738, which may target cancer cells that have a specific change (mutation) in the RAS gene. The goal is to see if it is safe and works against advanced or spreading solid tumors.
This trial tests whether RMC-6236 can treat advanced solid tumors that have specific RAS-related gene changes (especially certain KRAS G12 mutations). You may be able to join if your tumor’s DNA test shows the right mutation and your overall health is good enough for study visits.
This trial tests a new drug, VS-7375, for people with advanced non-small cell lung cancer that has a specific genetic change called KRAS G12D. It's for those who have already tried chemo and immunotherapy, and whose cancer has continued to grow.
This trial tests a new drug, RO7673396, for people with advanced solid tumors that have a RAS mutation. The goal is to see if the drug is safe and works against the cancer.
Hear when a new RAS Mutation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.